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ABSTRACT
Claudin3 is an integral component of the tight junction proteins in polarized 
epithelia. The expression of claudin3 was assessed in epithelial-derived tumors 
using Oncomine database. To determine the gene alteration during carcinogenesis, 
copy number alterations and mutations of claudin3 were evaluated using cBioPortal 
database. Claudin3 is overexpressed in several tumors including gynecological, 
bladder, breast and prostate carcinomas. 38% of the 163 evaluated studies show 
mutations and/or amplification of claudin3. 3D reconstruction of tissue samples 
following immunofluorescence analysis clearly demonstrated that, unlike in healthy 
tissues, claudin3 is mislocalized and unengaged in the formation of tight junction in 
tumor samples. These data strongly support the evaluation of unengaged claudin3 
as a target for the development of novel diagnostic probes, optical approaches for 
real time detection of tumoral tissues during surgery, and target therapeutic drugs.
INTRODUCTION
Claudins belong to a large family of integral 
membrane proteins stably integrated within the tight 
junctions (TJ), at the apical end of the lateral membrane of 
epithelial cells. The claudin-based junctions are not static 
and undergo continuous molecular remodeling becoming 
a cell signaling component involved in the establishment 
and maintenance of cell polarity, sealing the intercellular 
space between adjacent cells and regulating the solute 
movement across epithelial sheets [1]. The expression 
pattern of the claudins is usually tissue specific; however, 
most tissues express multiple claudins that can interact in 
either a homotypic or heterotypic fashion to form the TJ 
strand.
Claudins also have functions in receiving 
environmental cues and transmitting signals inside cells, 
supporting cell growth and proliferation [2]. Indeed, the 
cytoplasmic C-terminal PDZ binding domain directly 
interacts with cytoplasmic protein ZO-1, -2 and -3, 
connecting claudins to the actin cytoskeleton and the 
signaling pathways of the cell [3].
The majority of tumors are of epithelial origin and 
therefore, similar to non-transformed epithelial cells, 
quite immobile. However, tumor cells may increase their 
mobility by the process of epithelial-to-mesenchymal 
transition (EMT). Epithelial cells down-regulate some 
epithelial cell-specific genes such as E-cadherin, alter 
the cell-cell contact and up-regulate some mesenchymal 
genes including SNAIL, TWIST and SLUG, which in 
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particular promote migration and tolerance to a novel 
environment. Accordingly, there has been a description 
of alteration of TJ integrity and the down-regulation of 
different claudins, including claudin1 and claudin7, in 
a variety of epithelial tumors such as breast, esophagus 
and gastric cancers [4–6]. A claudin-low molecular 
subtype of breast cancer has been described with a 
concomitant upregulation of several EMT markers and 
an enrichment in stem cell features. This molecular 
subtype of breast malignancies is associated with poor 
prognosis in patients with high-grade invasive ductal 
carcinomas [7].
Surprisingly, the up-regulation of claudin3 and 4 in 
ovarian cancers [8], in uterine serous carcinomas [9], in 
colorectal cancers [10] and in breast cancers [11] has also 
been associated to tumorigenesis, though the role of the 
overexpressed claudins remains largely unexplained.
Alterations in the expression or epigenetic 
modulation of claudins affect apoptotic sensitivity to a 
number of apoptogens, invasiveness, and tumorigenicity 
in various cancer cells. It is noteworthy that dysregulated 
claudins directly result in several distinct abnormalities of 
tissue physiology.
The alteration of cell-cell contact leads to the loss 
of cell polarity, to the tissue disorganization and to the 
exposure of a number of extracellular signals such as those 
from growth factors. Also, in the absence of the apical-
basal polarity, epithelial cells that receive growth signals 
not only in the apical domain tend to proliferate by an out-
of-plane division promoted by the mis-orientation of the 
mitotic axis [12]. Thus, the loss of polarity in tumor tissues 
might suggest an altered localization of claudin in tumor 
cells.
We recently developed the IgGH6 antibody 
against the minor extracellular domain of claudin3, 
which is physiologically engaged in the cell-cell contact 
in the TJ. IgGH6 recognizes a subset of claudin3 
non-engaged in TJ formation [13]. Since TJ proteins 
serve as a physical barrier regulating paracellular 
permeability, their alteration may alter not only tumor 
infiltration but also tumor cell metastatization. This 
unengaged or mislocalized claudin3, if it exists in vivo, 
might represent not only a good biomarker of cancer 
progression but also a good target for the development 
of tumor directed therapy.
Here we analyzed the alterations of claudin3 
in terms of expression and localization in different 
epithelial-derived human tumors. The expression and 
genomic alterations were examined in public Oncomine 
and cBioPortal database, while immunofluorescence 
analysis using z-stack tool was used to unequivocally 
demonstrate that claudin3 in tumors, (as different authors 
have speculated), is not confined to TJ but is relocated 
along the surface of the cells. The alteration of claudin3 
localization is not due to its expression levels but it is an 
intrinsic characteristic of the neoplasia.
RESULTS
Claudin3 expression and genomic alterations in 
epithelial-derived tumors
An altered claudin3 expression has been reported in 
different tumors. Comparative gene expression analysis 
between tumor and normal tissues using the cancer 
microarray database and the data mining platform of 
Oncomine revealed that claudin3 is overexpressed in 
breast, esophageal, gastric, ovarian, lung and prostate 
cancers. The threshold was designated according to the 
following values: p-value <0.005, fold change 1.5, and top 
gene ranks 10% (Figure 1a). We next explored the genomic 
alterations of claudin3 by examining the mutational data 
publicly available in the cBioPortal database. CBioPortal 
collects all information on gene alteration in frequency, 
including deletions, amplification or multiple alterations, 
and on gene mutations of 681 cancer samples. This 
analysis identified only 23 low frequency missense and 
3 truncating mutations in claudin3 sequence in the 163 
studies analyzed (Figure 1b). Mutations mainly occurred 
in the primary central nervous system and lymphoma, 
which exerts the higher mutational profile. Overall, 10% 
of the examined samples contain missense mutations in 
claudin3 sequence (Figure 1c). Figure 1c correlates the 
expression level of claudin3 with missense mutations, 
suggesting that there is no relationship between mutation 
and overexpression. Claudin3 amplification was described 
in most analyzed tumors with a variable percentage, 
ranging from about 18% in neuroendocrine prostate cancer 
to 1% in other samples (Figure 1d).
Claudin3 expression in gynecological tumors
When we analyzed in more detail the available 
datasets of gynecological tumors, we observed the over-
expression of claudin3 in different histotypes of epithelial 
ovarian cancer, including serous, endometrioid, clear 
cell and mucinous (Figure 2a), while no significant 
changes was highlighted in uterine carcinomas including 
endometrioid and serous adenocarcinomas (Figure 2b).
Claudin3 expression was verified in fresh 
frozen biopsies collected in our tissue bank of serous 
ovarian and endometrial carcinomas. In High Grade 
Serous Ovarian Carcinoma (HGSOC) the expression 
of claudin3 is 4 fold higher than in healthy ovarian 
epithelia, where claudin3 is almost undetectable (Figure 
2c). Whereas no significant alteration in claudin3 
expression can be appreciated if, following the recently 
idea that HGSOC arise from fallopian tube, we compare 
HGSOC with healthy tube (Figure 2c). A slight increase 
is observed in Uterine Endometrial Serous Carcinoma 
(UESC) samples compared with normal endometrial 
epithelia (Figure 2d).
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Claudin3 is not confined to TJ in tumor samples
Several authors speculated that over-expressed 
claudins are not only confined to cell-cell contacts and 
may lead to a loss of epithelial cell polarization. To 
verify whether the expression alteration of claudin3 
affects its localization on cell membrane, we incubated 
a 20 μm section of fresh frozen biopsies of healthy and 
tumor tissues with the commercial antibody against 
the intracellular portion of claudin3. Of note, this 
antibody allows the staining of all expressed claudin3. 
As expected, immunofluorescent analysis confirms that 
healthy ovary tissue does not express detectable levels 
of claudin3 (Figure 3a) whereas 3D reconstruction of Z 
stack analysis of healthy endometrium shows a dense 
staining at the apical lateral side of normal epithelium, 
with claudin3 homogeneously distributed along the cell-
cell contact throughout the plasma membrane (Figure 
3b). Then, to characterize the effect of upregulation of 
claudin3 in tumor, we performed a 3D reconstruction of 
claudin3 localization in all HGSOC and UESC samples. 
Immunofluorescence does not allow to appreciate claudin3 
over-expression, but its disordered distribution on cell 
membrane certainly does. The membrane expression 
of claudin3 is also demonstrated by co-staining with 
anti claudin3 and WGA-lectin of 3D culture of UESC-
derived cells (Supplementary Figure 1). In tumor sections 
claudin3 is unevenly distributed and tight junctions are 
not clearly identified in the apical lateral side of cell-
cell contact (Figure 3a and 3b). We could not exclude 
that mislocalized claudin3 are engaged in a cell-cell 
contact structures. To address this point, we re-analysed 
the same tissue samples using IgGH6 antibody, recently 
developed in our laboratory. IgGH6 recognizes the minor 
extracellular domain of claudin3 and labels only the 
unengaged claudin3 [13]. Figure 4 shows that in normal 
Figure 1: Claudin3 is altered in tumors. (a) The comparison indicated the number of datasets with claudin3 mRNA overexpression 
(left column, red) and under expression (right column, blue) in cancer versus normal tissue. The threshold was designed with following 
parameters: p-value of 0,005, fold change of 1.5, and gene ranking of 10% Oncomine (www.oncomine.com). (b) claudin3 frequency 
mutations. (c) correlation between claudin3 expression level and genomic mutations. (d) alteration frequency of claudin3 signature was 
determined using the cBioPortal (http://www.cbioportal.org). The alteration frequency included deletions (blue) and amplification (red).
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tissues IgGH6 antibody does not recognize claudin3 
suggesting, in accordance with our previous results, that 
all claudin3 expressed on cell membrane are committed 
to the formation of tight junctions. In tumor samples, 
on the contrary, 3D tissue reconstruction clearly reveals 
that claudin3 is mislocalized and not involved in cell-cell 
contacts both in HGSOC and UESC samples (Figure 4). 
These data suggest that the up-regulation of claudin3 is not 
necessary for its mislocalization. Indeed, IgGH6 antibody 
recognizes claudin3 also in tumoral tissue, such as UESC, 
in which there is not a clear transcriptional up-regulation.
All these data, in agreement with the previous 
observations, support the idea that the dysregulation of 
claudin3 expression in tumoral tissue might play a role in 
the pathogenesis of cancer.
DISCUSSION
In this paper we analyzed the expression and 
localization of claudin3 in different healthy tissue and 
human tumor samples, using a combined approach based 
on in-silico evaluation of claudin3 gene expression and 
genomic alterations, RT-qPCR and immunofluorescence 
staining on fresh-frozen specimens. Our analysis, 
performed on a large dataset of human carcinomas and 
healthy tissues revealed a substantial dysregulation of 
claudin3 expression in all evaluated tumors and confirmed 
that the observed differential expression is tissue-specific 
and strictly dependent on cancer type [14]. According 
to the cBioPortal database examination, there was no 
direct correlation between claudin3 expression and its 
genomic alterations in terms of deletions, amplifications 
or single mutations, suggesting that claudin3 expression 
changes in tumors were not influenced by the gene 
mutational status. Importantly, we unquestionably 
demonstrated that in epithelial tumors claudin3 appears 
heterogeneously distributed outside the tight junctions, 
and this is apparently unrelated to its expression level. 
These altered localization with the presence of a subset 
of claudins outside the TJ, has been hypothesized as a 
consequence of the dis-regulation of the mitotic axis 
occurring in malignant proliferating cells, causing out-
of-plane division of tumor cells and aberrant exposure of 
junctional components [12]. This phenomenon, however, 
Figure 2: Claudin3 in gynecological tumors. (a-b) claudin3 analysis in different ovarian and uterine cancer histotype available in 
Oncomine datasets. (c-d) claudin3 expression evaluated by qRT-PCR in fresh frozen biopsies of ovarian and endometrial serous carcinomas 
and fallopian tube. (**P<0.003, *P <0.06 unpaired t test, n=5).
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Figure 3: Claudin3 is out of tight junctions in in tumor samples. 20 μm section of fresh frozen biopsies of healthy (a) and 
tumor (b) ovarian and uterine endometrial tissues were immunostained with a commercial anti-claudin3 antibody followed by anti-rabbit 
Alexa594. Nuclei are counterstained with DAPI. Z-stack images were recorded using a Zeiss Axiovert 200M epifluorescence microscope 
equipped with a Plan-Apochromat 63x/1.4 NA oil objective and ApoTome system. For 3D reconstructions and orthogonal projections, 
Z-stack images were elaborated with AxioVision Inside4D. Scale bar: 20 μm.
Figure 4: Mis-localized Claudin3 is a suitable target for tumor identification. (a-b) 20 μm section of fresh frozen biopsies 
of healthy and tumor ovarian and uterine endometrial tissues were immunostained with an IgGH6 antibody against minor extracellular 
domain of claudin3 followed by anti-human Alexa594. Nuclei are counterstained with DAPI. Z-stack images were recorded using a Zeiss 
Axiovert 200M epifluorescence microscope equipped with a Plan-Apochromat 63x/1.4 NA oil objective and ApoTome system. For 3D 
reconstructions and orthogonal projections, Z-stack images were elaborated with AxioVision Inside4D. Scale bar: 20 μm.
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has never been clearly addressed due to the lack of 
functional antibodies specific for claudin extracellular 
domains. Here we confirmed the claudin3 expression 
in fresh samples collected in our Institute, focusing 
on ovarian and endometrial serous carcinomas where 
claudin3 has been consistently reported as potential 
cancer biomarker and therapeutic target by our group and 
others [15–17]. Although public datasets used in our study 
refereed HGSOC biogenesis to ovarian epithelium, a new 
paradigm on the pathogenesis of HGSOC is emerging, 
which identifies the fallopian tube epithelium as a putative 
site of origin of this tumor [18]. Since we can not exclude 
this hypothesis, we also compared claudin3 expression in 
HGSOC with tube surface epithelium. Preliminary results 
show significant reduction in claudin3 expression (Romani 
C, unpublished results). Ovarian surface epithelium is a 
modified mesothelium in continuum with the mesothelial 
lining of the pelvic organs, and embryological distinct 
from Mullerian epithelia [19]. Not surprisingly claudin3 
is almost undetectable in healthy ovarian samples but 
abundantly expresses and properly engages in a cell-cell 
contact structures in Mullerian-derived tube epithelium. 
Of note here we show claudin localization in ovarian 
and uterine tumors but similar results were obtained also 
in other epithelial tumors including colon carcinomas 
(Corsini M. unpublish data).
The importance of expression of claudins and their 
localization in diagnostic is supported by the increasing 
number of papers suggesting a relation between claudin 
expression and tumor outcome. A claudinlow breast cancer 
subtype, which expressed low level of claudin4, claudin7 
and claudin3, has been identified using human tumor 
database. In contrast to the basal-like subtype, claudinlow 
tumors are more enriched in epithelial-to-mesenchymal 
transition features, immune system responses, and stem 
cell-associated biological processes [7]. Importantly, 
claudinlow tumors show some chemotherapy sensitivity 
and have a poor prognosis. Starting from these data, Prat 
et al. developed a genomic differentiation predictor for 
the classification of breast tumors. Moreover, an invasive 
ductal breast carcinoma subgroups has been characterized 
by immunohistochemistry analysis by the expression of 
Ki-67, cytokeratins (CK5 and CK18) and claudin7 [20]. 
Also the expression of claudin11 has been suggested as 
biomarker for advanced stage of cutaneous squamous 
carcinoma [21]. On these basis, we can speculate that the 
differential expression of claudins may reflect the distinct 
stages of tumor development and differentiation. A panel 
of antibodies against claudins could be used in diagnostic 
to complete the tumor characterization and to help the 
therapeutically choice. In this regard, the IgGH6 may 
be able to distinguish the expression of the claudin3 of 
healthy tissues, in which it is located in the TJ, from the 
tumor ones.
In summary, we can conclude that the 
transcriptional up-regulation of claudin3 is not related to 
its mislocalization and that the relocalization of claudins 
out of the TJ is in agreement with the loss of polarized 
morphology that characterizes epithelial cells undergoing 
neoplastic transformation.
Staining with IgGH6 human antibody, whose 
binding epitope is located within the minor ectodomain of 
claudin3, clearly proves the presence of extra-junctional 
claudin3 outside the cell-cell contact in transformed 
epithelia. Minor ectodomain is engaged in claudin-claudin 
homotypic interactions and becomes accessible only in 
tumor cells characterized by an alterate cell-cell junctions. 
This unengaged claudin3 represents a potential target both 
for antibody-based diagnostic probes.
To our knowledge, IgGH6 is the first molecule able 
to bind exclusively unengaged claudin3. IgGH6 represents 
an unvaluable tool to assess claudin3 mislocalization on 
epithelial-derived cancer cells.
MATERIALS AND METHODS
Oncomine and cBioPortal databases analysis
The public sites Oncomine (https://www.oncomine.
org) and cBioPortal (www.cbioportal.org) were used 
respectively for the analysis of expression and genomic 
alterations of claudin3. These provided access to data from 
more than 5,000 tumor samples from 163 cancer studies in 
the TCGA pipeline.
Tissue samples
Tissue samples were collected from patients 
undergoing surgery at the Division of Obstetric and 
Gynecology, ASST-Spedali Civili (Brescia, Italy), under 
a protocol approved by the institutional review board 
(study reference number: NP1284). The study was 
performed following the Declaration of Helsinki set of 
principles and was approved by the institutional Research 
Review Board-Ethic Committe. Written informed consent 
was obtained from each patient before collecting tissue 
samples. Tumor specimens of 5 uterine endometrial 
serous carcinoma (UESC) and of 5 high grade serous 
ovarian carcinoma (HGSOC) were collected at the time 
of primary surgery and snap frozen in liquid nitrogen. 
Normal endometrial (NE) tissue samples were obtained 
from 5 patients undergoing hysterectomy for benign 
pathologies. Five Normal ovarian (NO) samples were 
collected by scraping the surface epithelium of normal 
ovaries [22].
Quantification of claudin3 mRNA by RT-qPCR
Samples containing at least 70% of tumor cells 
were processed for RNA extraction using TRIzol Reagent 
(Invitrogen, Carlsbad, CA) followed by RNeasy MiniElute 
Cleanup kit (Qiagen). cDNA was generated from total RNA 
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using the SuperScriptII reverse transcriptase (Invitrogen) 
[23]. Quantitative PCR was performed with a Biorad 
CFX96 Real-Time PCR Detection System using iQ™ 
SYBR Green Supermix (Biorad, Hercules, CA). Data were 
recorded using Bio-Rad CFX Manager software (BioRad). 
Relative expression ratios were calculated by use of Pfaffl 
equation and Relative Expression Software Tool. The 2-
ΔΔCt method was applied to calculate changes in claudin3 
expression. The mRNA expression levels of claudin3 
were normalized to the geometric mean of HPRT1 and 
PPIA transcript levels. TaqMan Gene Expression Assay 
for claudin3 was obtained from Applied Biosystems as 
Assay-on-Demand product (ID: Hs00265816_s1). HPRT1 
(primers for/rev: CTGGAAAGAATGTCTTGATTGTG/
GACCTTGACCATCTTTGGATTA and probe ACTGCC 
TGACCAAGGAAAGCAAAGTCT) and PPIA (primers 
for/rev: GAGGAAAACCGTGTACTATTAGC/GGGAC 
CTTGTCTGCAAAC and probe CCACCGTGTTCTTCG 
ACATTGCCGT) assays were designed with Beacon 
Designer software (Premier Biosoft, Palo Alto, CA, USA).
Immunofluorescence staining
Snap frozen tissue sections were fixed in 3% 
paraformaldehyde/2% sucrose in PBS, permeabilized 
with 0.5% Triton-X100, and saturated with goat 
serum in PBS. Samples were incubated with anti-
claudin3 (Invitrogen) or with IgGH6 anti-claudin3 
[13] over-night at 4°C followed by Alexa Fluor 594 
anti-rabbit IgG (Molecular Probes, Eugene, OR). Cells 
membranes were stained with WGA lectin-Alexa Fluor 
488 (Molecular Probes, Eugene, OR) and nuclei were 
counterstained with 4’,6-diamidino,2-phenylindole 
(DAPI, Sigma). Samples were analyzed using Zeiss 
Axiovert 200M epifluorescence microscope equipped 
with Apotome system, Plan-Neofluar 20x/0.5 NA and 
Plan-Apochromat 63x/1.4 NA oil objectives. Z-stack 
images were elaborated with AxioVision Inside4D 
module (Carl Zeiss) [24].
Abbreviations
Tight junction (TJ), epithelial-to-mesenchymal 
transition (EMT). uterine endometrial serous carcinoma 
(UESC), high grade serous ovarian carcinoma (HGSOC), 
Normal endometrial (NE), Normal ovarian (NO), 
Hypoxanthine Phosphoribosyltransferase 1 (HPRT1), 
Peptidylprolyl isomerase A (PPIA), 4’,6-diamidino,2-
phenylindole (DAPI).
Author contributions
MC, CR and SM conceived and performed all of the 
experiments, analyzed the data and wrote the paper. AR, 
FO, ADS, MP contributed to the data analyses and paper 
discussion.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
FUNDING
This work was supported in part by a grant from: 
Associazione Italiana per la Ricerca sul Cancro (AIRC IG 
2015), grant 17276 to SM, University of Brescia H&W 
projects to SM and MC; EULO Foundation grant to FO 
and from NIH U01 CA176067-01A1, the Deborah Bunn 
Alley Foundation, the Tina Brozman Foundation, the 
Discovery to Cure Foundation and the Guido Berlucchi 
Foundation to ADS.
REFERENCES
1. Van Itallie CM, Anderson JM. The molecular physiology of 
tight junction pores. Physiology (Bethesda). 2004; 19:331-
8. https://doi.org/10.1152/physiol.00027.2004.
2. Tsukita S, Furuse M, Itoh M. Multifunctional strands in 
tight junctions. Nat Rev Mol Cell Biol. 2001; 2:285-93. 
https://doi.org/10.1038/35067088.
3. Webb PG, Spillman MA, Baumgartner HK. Claudins play 
a role in normal and tumor cell motility. BMC Cell Biol. 
2013; 14:19. https://doi.org/10.1186/1471-2121-14-19.
4. Kominsky SL, Argani P, Korz D, Evron E, Raman V, 
Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S. 
Loss of the tight junction protein claudin-7 correlates with 
histological grade in both ductal carcinoma in situ and 
invasive ductal carcinoma of the breast. Oncogene. 2003; 
22:2021-33. https://doi.org/10.1038/sj.onc.1206199.
5. Usami Y, Chiba H, Nakayama F, Ueda J, Matsuda Y, 
Sawada N, Komori T, Ito A, Yokozaki H. Reduced 
expression of claudin-7 correlates with invasion and 
metastasis in squamous cell carcinoma of the esophagus. 
Human Pathol. 2006; 37:569-77.
6. Wang H, Yang X. The expression patterns of tight junction 
protein claudin-1, -3, and -4 in human gastric neoplasms 
and adjacent non-neoplastic tissues. Int J Clin Exp Pathol. 
2015; 8:881-7.
7. Prat A, Parker JS, Karginova O, Fan C, Livasy C, 
Herschkowitz JI, He X, Perou CM. Phenotypic and 
molecular characterization of the claudin-low intrinsic 
subtype of breast cancer. Breast Cancer Res. 2010; 12:R68. 
https://doi.org/10.1186/bcr2635.
8. Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alo PL, 
Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin 
PJ. Tight junction proteins claudin-3 and claudin-4 are 
frequently overexpressed in ovarian cancer but not in 
ovarian cystadenomas. Clin Cancer Res. 2003; 9:2567-75.
9. Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel 
ER, McKenney JK, Hennings L, Comper F, Bandiera E, 
Pecorelli S. Overexpression of claudin-3 and claudin-4 
Oncotarget18453www.oncotarget.com
receptors in uterine serous papillary carcinoma: novel 
targets for a type-specific therapy using Clostridium 
perfringens enterotoxin (CPE). Cancer. 2007; 109:1312-22. 
https://doi.org/10.1002/cncr.22536.
10. de Oliveira SS, de Oliveira IM, De Souza W, Morgado-
Diaz JA. Claudins upregulation in human colorectal cancer. 
FEBS Lett. 2005; 579:6179-85. https://doi.org/10.1016/j.
febslet.2005.09.091.
11. Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, 
Argani P, Sukumar S. Clostridium perfringens enterotoxin 
elicits rapid and specific cytolysis of breast carcinoma cells 
mediated through tight junction proteins claudin 3 and 4. 
Am J Pathol. 2004; 164:1627-33. https://doi.org/10.1016/
S0002-9440(10)63721-2.
12. Royer C, Lu X. Epithelial cell polarity: a major gatekeeper 
against cancer? Cell Death Differ. 2011; 18:1470-7. https://
doi.org/10.1038/cdd.2011.60.
13. Romani C, Cocco E, Bignotti E, Moratto D, Bugatti A, 
Todeschini P, Bandiera E, Tassi R, Zanotti L, Pecorelli S, 
Sartori E, Odicino FE, de Marco A, et al. Evaluation of a 
novel human IgG1 anti-claudin3 antibody that specifically 
recognizes its aberrantly localized antigen in ovarian 
cancer cells and that is suitable for selective drug delivery. 
Oncotarget. 2015; 6:34617-28. https://doi.org/10.18632/
oncotarget.5315.
14. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: 
expression in normal and neoplastic tissues. BMC Cancer. 
2006; 6:186. https://doi.org/10.1186/1471-2407-6-186.
15. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti 
E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, 
Tian E, Cannon MJ, et al. Gene expression profiles in 
primary ovarian serous papillary tumors and normal ovarian 
epithelium: identification of candidate molecular markers 
for ovarian cancer diagnosis and therapy. Int J Cancer. 
2004; 112:14-25. https://doi.org/10.1002/ijc.20408.
16. Suzuki H, Kondoh M, Takahashi A, Yagi K. Proof 
of concept for claudin-targeted drug development. 
Ann N Y Acad Sci. 2012; 1258:65-70. https://doi.
org/10.1111/j.1749-6632.2012.06503.x.
17. English DP, Santin AD. Claudins overexpression in ovarian 
cancer: potential targets for Clostridium Perfringens 
Enterotoxin (CPE) based diagnosis and therapy. Int J 
Mol Sci. 2013; 14:10412-37. https://doi.org/10.3390/
ijms140510412.
18. Kurman RJ, Shih Ie M. Molecular pathogenesis and 
extraovarian origin of epithelial ovarian cancer—shifting 
the paradigm. Human Pathol. 2011; 42:918-31. https://doi.
org/10.1016/j.humpath.2011.03.003.
19. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. 
Ovarian surface epithelium: biology, endocrinology, and 
pathology. Endocr Rev. 2001; 22:255-88. https://doi.
org/10.1210/edrv.22.2.0422.
20. Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke 
C, Soares FA, Brentani MM. Prognostic significance of 
CD24 and claudin-7 immunoexpression in ductal invasive 
breast cancer. Oncol Rep. 2012; 27:28-38. https://doi.
org/10.3892/or.2011.1477.
21. Nissinen L, Siljamaki E, Riihila P, Piipponen M, Farshchian 
M, Kivisaari A, Kallajoki M, Raiko L, Peltonen J, Peltonen 
S, Kahari VM. Expression of claudin-11 by tumor cells in 
cutaneous squamous cell carcinoma is dependent on the 
activity of p38delta. Exp Dermatol. 2017; 26:771-7. https://
doi.org/10.1111/exd.13278.
22. Bignotti E, Calza S, Tassi RA, Zanotti L, Bandiera E, 
Sartori E, Odicino FE, Ravaggi A, Todeschini P, Romani 
C. Identification of stably expressed reference small non-
coding RNAs for microRNA quantification in high-grade 
serous ovarian carcinoma tissues. J Cell Mol Med. 2016; 
20:2341-8.
23. Grillo E, Ravelli C, Corsini M, Ballmer-Hofer K, 
Zammataro L, Oreste P, Zoppetti G, Tobia C, Ronca 
R, Presta M, Mitola S. Monomeric gremlin is a novel 
vascular endothelial growth factor receptor-2 antagonist. 
Oncotarget. 2016; 7:35353-35368. https://doi.org/10.18632/
oncotarget.9286.
24. Ravelli C, Grillo E, Corsini M, Coltrini D, Presta M, 
Mitola S. β3 integrin promotes long-lasting activation 
and polarization of vascular endothelial growth factor 
receptor 2 by immobilized ligand. Arterioscler Thromb 
Vasc Biol. 2015; 35:2161-71. https://doi.org/10.1161/
ATVBAHA.115.306230.
